Lakhmir S. Chawla, M.D. Receives the International Vicenza Award
July 01 2015 - 8:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that Lakhmir “Mink”
S. Chawla, M.D., the Company’s Chief Medical Officer, received the
International Vicenza Award for Critical Care Nephrology at the
33rd Course on Critical Care Nephrology in June 2015. This award
recognizes individuals who have made seminal clinical research
advancements that have significantly improved the care of
critically ill patients with acute kidney injury (AKI) and have
been adopted worldwide.
Dr. Chawla was selected as the recipient of the Vicenza Award
for his contributions to the development of the renal angina model,
the development and standardization of the furosemide stress test,
the link between AKI and chronic kidney disease (CKD), and the use
of angiotensin II in the treatment of high-output shock. Dr. Chawla
is the tenth recipient to receive the Vicenza Award.
Prior to his appointment at La Jolla, Dr. Chawla was an
Associate Professor of Medicine at the George Washington
University, where he had dual appointments in the Department of
Anesthesiology and Critical Care Medicine and in the Department of
Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla
was also the Chief of the Division of Intensive Care Medicine at
the Washington D.C. Veterans Affairs Medical Center.
Dr. Chawla has been an active investigator in the field of
critical care nephrology since 2002. His research has focused on
shock, inflammation, AKI epidemiology and outcomes, the link
between AKI and CKD, and AKI risk assessment. He is also a leading
researcher in the field of AKI biomarkers and functional kidney
testing.
“On behalf of the entire La Jolla team, I would like to
congratulate Mink on receiving this prestigious award,” said George
F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of
La Jolla. “Mink has made many valuable contributions to the field
of medicine, and we are honored to have him on our team.”
Professors Claudio Ronco, M.D. and Rinaldo Bellomo, MBBS, M.D.,
FRACP, FCICM, PGDipEcho presented the award. Professor Ronco
founded the International Renal Research Institute of Vicenza that
has hosted more than 100 fellows from all over the world and is
renowned for the interdisciplinary nature of the research carried
out in its many laboratories. Professor Bellomo is the Director of
Intensive Care Research at the Austin Hospital in Melbourne, the
Founding Chair of the Australian and New Zealand Intensive Care
(ANZIC) Society Clinical Trials Group and the current Co-Director
of the ANZIC Research Centre.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
several product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension and hepatorenal
syndrome. LJPC-401 is La Jolla’s novel formulation of hepcidin for
the potential treatment of conditions characterized by iron
overload, such as hereditary hemochromatosis and beta thalassemia.
LJPC-30Sa and LJPC-30Sb are La Jolla’s next-generation gentamicin
derivatives for the potential treatment of serious bacterial
infections and rare genetic disorders, such as cystic fibrosis and
Duchenne muscular dystrophy. For more information on La Jolla,
please visit www.ljpc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150701005522/en/
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive
Officer858-207-4264gtidmarsh@ljpc.comorDennis M. MulroyChief
Financial Officer858-433-6839dmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2023 to Apr 2024